Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function

Journal of Crohn's and Colitis

Volumn 6, Issue 6, 2012, Pages 655-659

  Hindorf, Ulf ^a   Appell, Malin Lindqvist ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Genotype; Inflammatory bowel diseases; Phenotype; Thiopurine methyltransferase; Thiopurines

Indexed keywords

THIOPURINE METHYLTRANSFERASE;

ARTICLE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; SWEDEN;

6-MERCAPTOPURINE; AZATHIOPRINE; BIOLOGICAL MARKERS; COHORT STUDIES; GENETIC MARKERS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METABOLIC DETOXICATION, DRUG; METHYLTRANSFERASES; PHENOTYPE; RETROSPECTIVE STUDIES; SWEDEN;

EID: 84862170980     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.11.014     Document Type: Article

References (18)

1. Lindqvist M., Hindorf U., Almer S., Peterson C. Thiopurines in inflammatory bowel disease - the role of pharmacogenetics and therapeutic drug monitoring. Curr Pharmacogenet 2006, 4:285-300.
2. Ford L.T., Berg J.D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol Apr. 2010, 63(4):288-295.
3. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst Dec. 1 1999, 91(23):2001-2008.
4. *23. Pharmacogenet Genomics Oct. 2007, 17(10):891-895.
5. *24). Pharmacogenet Genomics Oct. 2008, 18(10):887-893.
6. *26 (208F->L), a novel mutation detected in a Chinese. Br J Clin Pharmacol Jul. 2009, 68(1):120-123.
7. Feng Q., Vannaprasaht S., Peng Y., Angsuthum S., Avihingsanon Y., Yee V.C., et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol Apr. 1 2010, 79(7):1053-1061.
8. *28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics Nov. 2010, 20(11):700-707.
9. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet Sep. 1980, 32(5):651-662.
10. Lennard L., Chew T.S., Lilleyman J.S. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol Nov. 2001, 52(5):539-546.
11. Lindqvist M., Haglund S., Almer S., Peterson C., Taipalensu J., Hertervig E., et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics Apr. 2004, 14(4):261-265.
12. Schaeffeler E., Fischer C., Brockmeier D., Wernet D., Moerike K., Eichelbaum M., et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics Jul. 2004, 14(7):407-417.
13. Hindorf U., Lindqvist M., Peterson C., Soderkvist P., Strom M., Hjortswang H., et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut Oct. 2006, 55(10):1423-1431.
14. Gardiner S.J., Gearry R.B., Begg E.J., Zhang M., Barclay M.L. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol Jun. 2008, 6(6):654-660. (quiz 04).
15. Hindorf U., Andersson P. How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?. Scand J Gastroenterol Oct. 2011, 46(10):1215-1221.
16. Hindorf U., Peterson C., Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit Dec. 2004, 26(6):673-678.
17. Wright S., Sanders D.S., Lobo A.J., Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut Aug. 2004, 53(8):1123-1128.
18. von Ahsen N., Armstrong V.W., Behrens C., von Tirpitz C., Stallmach A., Herfarth H., et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem Dec. 2005, 51(12):2282-2288.